Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol

Pharmazie

Volumn 62, Issue 10, 2007, Pages 760-766

  Krämer, Irene ^a,b   Schwabe, A ^a   Lichtinghagen, R ^c   Kamin, W ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; DEOXYRIBONUCLEASE; DORNASE ALFA; EDETATE DISODIUM; IPRATROPIUM BROMIDE; SALBUTAMOL;

ARTICLE; COLORIMETRY; CYSTIC FIBROSIS; DRUG DETERMINATION; DRUG FORMULATION; DRUG MIXTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NEBULIZER; OSMOLALITY; PH MEASUREMENT; PHYSICAL CHEMISTRY;

ADMINISTRATION, INHALATION; ALBUTEROL; ANTI-ASTHMATIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYRIBONUCLEASE I; DRUG COMBINATIONS; DRUG INCOMPATIBILITY; HYDROGEN-ION CONCENTRATION; IPRATROPIUM; NEBULIZERS AND VAPORIZERS; OSMOLAR CONCENTRATION; PHARMACEUTICAL SOLUTIONS;

EID: 35348953759     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2007.10.7027     Document Type: Article

References (18)

1. Beasley R, Rafferty P, Holgate ST (1988) Adverse reaction to the non-drug constituents of nebuliser solutions. Br J Clin Pharmacol 25: 283-287.
2. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, etal. For the society task force on the use of nebulizers (2001) European Respiratory Society guidelines on the use of nebulizers. Eur Respir J 18: 228-242.
3. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Fachinformation Atrovent® LS 04/2005; Fachinformation Atrovent® Feriginhalat 04/2005.
4. Bontempo JA (1997) Formulation Development. In: Bontempo JA (ed.) Development of Biopharmaceutical Parenteral Dosage Forms. Marcel Dekker Inc. New York
5. Clay MM, Pavia D, Newman SP, Lennard-Jones T, Clarke SW (1983) Assessment of jet nebulizers for lung aerosol therapy. Lancet 2: 592-594.
6. EMEA Guideline on the pharmaceutical quality of inhalation and nasal products: http://www.emea.eu.int/pdfs/human/qwp/4931305en.pdf (16. 05. 2006)
7. GlaxoSmithKhne GmbH & Co. KG, München, Fachinformation Sultanol® Fertiginhalat, Sultanol® forte Fertiginhalat, Sultanol® Inhalationslösung 04/2004.
8. Hoffmann-La Roche AG, Grenzach-Wyhlen, Fachinformation Pulmozyme® 06/2004.
9. Jacobson GA, Peterson GM (1995) Stability of ipratropium bromide and salbutamol nebuliser admixtures. Int J Pharm Pract 3: 169-173.
10. Kamin W, Schwabe A, Krämer I (2006) Inhalation solutions-which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulisers. J Cyst Fibros 5: 205-213.
11. Lichtinghagen R (2006) Determination of Pulmozyme® (dornase alpha) stability using a kinetic colorimetric DNase I activity assay. Eur J Pharm and Biopharm 63: 365-368.
12. McEvoy (ed.) AHFS Drug Information 2006. American Society of Health-System Pharmacists, Bethesda 2006.
13. McKenzie J, Gronberg S, Cruz Rivera M, Hoag J (2002) Budesonide inhalation suspension can be nebulized with solutions containing albuterol sulphate (poster). Chest 122 (Suppl.): 183S.
14. Nagtegaal JE, De Jong A, De Waard WJ, Van der Meer YG (1997) Formulation and shelf life of two solutions for inhalation. Ziekenhuisfarmacie 13: 23-29.
15. Schwabe A, Krämer I, Lichtinghagen R, Kamin W (2005) Physikalischchemische Kompatibilität der Inhalationslösung Pulmozyme® mit Atrovent® LS und Sultanol®. Krankenhauspharmazie 6: 240.
16. Shire SJ (1996) Stability characterization and formulation development of recombinant human deoxyribonuclease I [Pulmozyme®, (Dornase alfa)]. In: Pearlman R. Wang, YJ (Eds.) Pharmaceutical Biotechnology. Vol. 9 Formulation, characterization, and stability of protein drugs. Plenum Press, New York pp. 393-425.
17. Smaldone GC, McKenzie J, Cruz Rivera M (2000) Effect of nebulizer volume on drug delivery: budesonide inhalation suspension. Meeting of the American Thoracic Society (personal communication).
18. van den Bemt PMLA, de Bijl G, Langen MCJ, van Roon, EN (1997) Validation of two methods for the analysis of salbutamol/ipratropium inhalation fluid. Ziekenhuisfarmacie 13: 92-95.